[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cancer-locally-advanced-or-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cancer-locally-advanced-or-metastatic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100616951","phase-2-radioembolization-with-intra-arterial-angiotensin-ii-to-improve-tumor-absorbed-dose-radiant-100616951",false,"NCT07312292","Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose","RADIANT","Inclusion criteria:\n\n* Patients diagnosed with primary or metastatic liver tumors (any histological type).\n* A clinical indication for radioembolization.\n* Liver tumors with a diameter ≥ 2 cm.\n* Age ≥ 18 years.\n* Competent and able to provide own informed consent (no legally designated representative).\n* Written informed consent.\n\nExclusion criteria:\n\n* Any serious comorbidity preventing the safe administration of angiotensin II (AT-II). This includes:\n\n  1. Uncontrolled hypertension.\n  2. Treatment with ≥ 3 antihypertensive drugs.\n  3. Arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months.\n* Current use of angiotensin-converting enzyme (ACE) inhibitors.\n* Current use of angiotensin II receptor blockers (ARBs).\n* Known hypercoagulable state (i.e., thrombophilia).\n* History of severe peripheral vascular disease.\n* Known hypersensitivity to the active substance in Giapreza: angiotensin II.\n* Known hypersensitivity to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid.\n* Any serious and\u002For chronic liver disease preventing the safe administration of radioembolization.\n* Uncorrectable extrahepatic deposition of scout dose activity; activity in the falciform ligament, portal lymph nodes, and gallbladder is accepted.\n* Pregnancy or breastfeeding.\n* Body weight over 150 kg (because of maximum table load).\n* Known severe allergy to intravenous contrast fluids.\n* Participation in another investigational study which may compromise any endpoint of the study.\n* Any other significant comorbidity or medical condition that may compromise the safety of radioembolization.","ALL","18 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization.\n\nThe main questions it aims to answer are:\n\n* Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver?\n* Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do?\n* First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer technetium 99mTc macroaggregated albumin (99mTc-MAA) will be injected into the liver through an artery. On the same day, a single-photon emission computed tomography (SPECT)\u002FCT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks.\n* Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot.\n* After treatment: Participants will receive a Positron Emission Tomography (PET)\u002FCT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT\u002FCT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor.\n\nAll monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.",[27,28],"Liver Cancer (Locally Advanced or Metastatic)","Liver Cancer Adult",[30,31,32],"Radioembolization","Angiotensin II","yttrium-90","RECRUITING","2026-03-24",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":37},"2026-01-01",{"date":41,"type":21},"2027-11-01",{"name":43,"class":44},"Niek Wijnen","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100622993","phase-1-a-study-of-sh009-injection-in-patients-with-advanced-solid-tumors-100622993","NCT07390838","A Study of SH009 Injection in Patients With Advanced Solid Tumors.","An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH009 Injection in Patients With Advanced Solid Tumors.","Inclusion Criteria:\n\n* (1) Age≥18 years old at the time of informed consent, male or female;\n* (2) Subjects with histologically confirmed locally advanced, recurrent, or metastatic solid tumors (including but not limited to colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer, breast cancer, non-small cell lung cancer, esophageal cancer, etc.) who have experienced disease progression or intolerance to at least one prior line of systemic therapy, and for whom no acceptable standard therapy exists or who cannot benefit from or tolerate standard therapy;\n* (3) Subjects must have at least one measurable lesion per RECIST 1.1 criteria. A lesion that has been previously irradiated can only be considered measurable if there is documented progression at that site following radiotherapy;\n* (4) Archival tumor tissue samples are available, or the subject agrees to undergo a tumor biopsy for the determination of PD-L1 and CD47 expression levels and other biomarker analyses;\n* (5) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2;\n* (6) Life expectancy ≥12 weeks;\n* (7) Bone marrow function meets the following criteria: neutrophil count ≥ 1.5 × 10\\^9\u002FL; platelet count ≥ 90 × 10\\^9\u002FL (platelet count ≥ 75 × 10\\^9\u002FL in patients with liver cancer); hemoglobin (Hb) ≥ 90 g\u002FL;\n* (8) Liver function meets the following criteria: total bilirubin(TBIL) ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN for subjects with Gilbert's syndrome); aspartate aminotransferase (AST) and alanine and aminotransferase (ALT) ≤ 3 × ULN (ALT and AST ≤ 5 × ULN for subjects with liver cancer or liver metastases);\n* (9) Renal function meets the following criteria: serum creatinine clearance(CLcr) ≥ 50 mL\u002Fmin (calculated according to Cockcroft-Gault formula); urine dipstick test results show that urine protein \\\u003C 2 +, urine protein ≥ 2 + subjects should undergo 24-hour urine collection and urine protein content \\\u003C 1g within 24 hours;\n* (10) Coagulation function meets the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5× ULN;\n* (11) Female subjects of childbearing potential must use effective contraception during the trial and for 6 months after the last dose, and have a negative pregnancy test within 7 days before treatment initiation (except those who are surgically sterilized or postmenopausal). Male subjects must agree to use effective contraception during the trial and for 6 months after the last dose;\n* (12) The subject is fully informed about this trial before its commencement and voluntarily signs and dates the informed consent form.\n\nExclusion Criteria:\n\n* (1) Prior exposure to any CD47 antibody, SIRPα antibody, or CD47\u002FSIRPα recombinant protein;\n* (2) Prior treatment with adoptive cellular therapies such as CAR-T, TCR-T, or TIL. Prior administration of an anti-cancer vaccine, or use of live or live-attenuated vaccines within 4 weeks prior to the first dose;\n* (3) Systemic anti-tumor therapies within the specified timeframes prior to the first dose of study drug: Chemotherapy, antibody-based targeted therapy, endocrine therapy, or immunotherapy within 3 weeks. Mitomycin or nitrosoureas within 6 weeks. Oral fluoropyrimidines (e.g., S-1, capecitabine) and small molecule targeted agents within 2 weeks or 5 half-lives of the drug (whichever is longer).Chinese\u002Fherbal medicines with anti-cancer activity indicated in their labeling must be discontinued prior to enrollment. Prior radical radiotherapy within 3 months before study drug administration is excluded. Palliative radiotherapy administered within 2 weeks prior to dosing is allowed if the dose meets local palliative care standards and the radiation field covers less than 30% of the bone marrow area;\n* (4) Received any investigational drug within 28 days before administration of this trial, or participated in another clinical study at the same time, except for the following circumstances: the patient participated in an observational, non-interventional clinical study, or was in the follow-up period after the end of treatment in an interventional clinical study but the drug withdrawal had exceeded the washout period;\n* (5) Had major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks before the first administration, or needed to undergo elective surgery during the trial period;\n* (6) Patients who received systemic glucocorticoids (dexamethasone \\> 10 mg\u002F day or equivalent dose of the same drug) or other immunosuppressive therapy within 14 days before the first administration; except for topical, ocular, intra-articular, intranasal, and inhaled glucocorticoids; short-term use of glucocorticoids for prophylactic treatment (e.g., prevention of contrast allergy);\n* (7) Symptomatic brain parenchymal or leptomeningeal metastases, deemed by the investigator as unsuitable for enrollment;\n* (8) Prior immunotherapy with ≥Grade 3 irAE or ≥Grade 2 immune-related myocarditis;\n* (9) Severe or uncontrolled systemic disease, including but not limited to: uncontrolled pleural or peritoneal effusion; uncontrolled diabetes; ventricular arrhythmia requiring intervention; acute coronary syndrome, congestive heart failure, stroke, or other ≥Grade 3 cardiovascular event within 6 months; NYHA Class ≥II or LVEF \\\u003C50%; clinically significant QTcF prolongation or arrhythmia risk (baseline QTcF \\>450 msec for males or \\>470 msec for females); clinically uncontrolled hypertension (SBP \\>160 mmHg and\u002For DBP \\>90 mmHg after treatment) as judged by the investigator. Subjects judged by the investigator as unsuitable due to any such condition;\n* (10) History of pneumonia requiring hormone therapy or interstitial lung disease (including past and current history); active pulmonary infection;\n* (11) Active infection requiring intravenous anti-infective therapy within 1 week prior to study drug administration (fever attributed to the tumor per investigator's judgment is acceptable). History of self-limited infections that have resolved is acceptable;\n* (12) Active Hepatitis B, Hepatitis C, or syphilis infection. Subjects positive for HBeAb or HBsAg are eligible if HBV-DNA ≤200 IU\u002FmL. Subjects positive for HCV-Ab are eligible if HCV-RNA ≤ the upper limit of normal at the research center. Subjects with hepatocellular carcinoma and HBV-DNA ≥2000 IU\u002FmL must receive antiviral\u002Fhepatoprotective therapy first and can only enroll after HBV-DNA decreases to \\\u003C2000 IU\u002FmL;\n* (13) History of primary immunodeficiency, including positive human immunodeficiency virus (HIV) test, or suffering from other acquired, congenital immunodeficiency diseases;\n* (14) History of other malignancies within 5 years prior to the first dose, except for:\n\n  a) Any other invasive malignancy, treated with curative intent, with a disease-free interval \\>3 years and deemed by the investigator not to affect efficacy evaluation for the current tumor. b) Adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or other locally cured cancers;\n* (15) History or presence of autoimmune disease within 2 years, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis or high risk (e.g., post-transplant immunosuppression). Exceptions: stable type 1 diabetes on fixed-dose insulin; autoimmune hypothyroidism on hormone replacement only; skin conditions not requiring systemic treatment (e.g., eczema, rash covering\\\u003C10% BSA, psoriasis without ocular symptoms);\n* (16) Arterial thromboembolic events within 6 months prior to the first dose, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or other serious thromboembolism within 3 months prior to the first dose (catheter-related or superficial venous thrombosis is not considered \"serious\"). Receiving thrombolytic or anticoagulant therapy for high thrombotic risk;\n* (17) Subjects who had receive allogeneic hematopoietic stem cell transplantation or solid organ transplantation (except corneal transplant);\n* (18) According to CTCAE 5.0, adverse reactions from previous anti-tumor therapy have not yet returned to ≤ grade 1 (except for toxicities which are judged by researchers to be safe, such as hair loss, pigmentation, hypothyroidism stabilized by hormone replacement therapy and peripheral neuropathy (need to recover to ≤ grade 2)). Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the study drug may be allowed after consultation with the medical monitor;\n* (19) Known history of severe hypersensitivity to macromolecular protein preparations\u002Fmonoclonal antibodies(CTCAE v5.0 Grade ≥3), or any component of the study drug;\n* (20) Known alcohol and\u002For drug dependence, or any other condition deemed by the investigator to affect the safety or compliance of the study treatment, including but not limited to psychiatric disorders;\n* (21) Pregnant or lactating women.",{"count":54,"type":21},150,[56],"PHASE1","Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors",[27,59,60,61,62,63,64],"Lung Cancer (NSCLC)","Head and Neck Cancer Squamous Cell Carcinoma","Breast Cancer (Locally Advanced or Metastatic)","Esophageal Cancer","Gastric Cancer (GC)","Solid Tumor Malignancies","2026-01-28",{"date":67,"type":37},"2026-02-05",{"date":69,"type":37},"2025-05-16",{"date":71,"type":21},"2028-12-30",{"name":73,"class":74},"Nanjing Sanhome Pharmaceutical, Co., Ltd.","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100612936","phase-1-immune-cell-therapy-for-advanced-solid-tumors-100612936","NCT07260058","Immune Cell Therapy for Advanced Solid Tumors","Clinical Study on the Safety and Efficacy of Autologous Immune Cell Therapy for Advanced Solid Tumors","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. The participant must voluntarily participate in the study and provide written informed consent。\n2. Age ≥ 18 years, male or female.\n3. Histologically and\u002For cytologically confirmed locally advanced or metastatic solid tumor: lung cancer, liver cancer, colorectal cancer, or breast cancer.\n4. ECOG (Eastern Cooperative Oncology Group) performance status score ≤ 2.\n5. Life expectancy ≥ 3 months.\n6. Has not received any other cellular immunotherapy within 3 months prior to enrollment.\n7. Has at least one measurable lesion according to RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1.\n8. Adequate organ function, defined as follows:\n\nHematology:\n\nWhite Blood Cell (WBC) count \\> 3.5 × 10⁹\u002FL Lymphocyte count \\> 0.9 × 10⁹\u002FL Monocyte count \\> 0.16 × 10⁹\u002FL Absolute Neutrophil Count (ANC) \\> 1.5 × 10⁹\u002FL Platelet (PLT) count \\> 75 × 10⁹\u002FL Hemoglobin (HB) \\> 75 g\u002FL Blood Biochemistry： Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)\n\nCoagulation:\n\nProthrombin Time (PT) and International Normalized Ratio (INR) ≤ 1.5 × ULN\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Prior receipt of any salvage chemotherapy, implanted intraperitoneal chemotherapy, targeted therapy, or biological immunotherapy (except: patients whose disease progressed more than 6 months after completing adjuvant, neoadjuvant, or radiosensitizing chemotherapy, or more than 1 month after intraperitoneal chemoperfusion\u002Fwash, are eligible, provided chemotherapy-related toxicities have recovered to Grade 1 or below, excluding alopecia).\n2. Major surgical procedure within 4 weeks prior to enrollment, with incomplete recovery from side effects.\n3. History of any active malignancy within 5 years, except for the specific cancer under investigation in this trial and cured localized tumors such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, and prostate carcinoma in situ.\n4. Presence of more than a small amount of pericardial effusion, or uncontrolled pleural or peritoneal effusion, defined as: detectable by physical examination at screening, or requiring therapeutic paracentesis during the screening period.\n5. Inability to tolerate peripheral blood collection due to various reasons (e.g., severe coronary heart disease, inability to establish peripheral venous access).\n6. Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure \\> NYHA (New York Heart Association) Class III, or severe arrhythmia.\n7. Active infection, unexplained fever ≥ 38.5°C within 7 days prior to medication, or baseline white blood cell count \\> 15×10⁹\u002FL; OR any severe acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy at screening (except for active hepatitis).\n8. Any active autoimmune disease or history of autoimmune diseases (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; Patients with vitiligo; Patients with childhood asthma that has completely resolved in adulthood without any intervention are eligible; Asthma requiring bronchodilator medical intervention is excluded). Patients are eligible if: they have a history of autoimmune-related hypothyroidism and are on stable thyroid hormone replacement therapy; or have type I diabetes controlled by insulin therapy.\n9. History of drug allergy.\n10. Pregnant or lactating women; OR women of childbearing potential or men with pregnant partners who are unwilling to use adequate contraception during the planned trial period (from the screening visit until 120 days after the last study treatment).\n11. History of organ transplantation.\n12. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.",{"count":83,"type":21},48,[56,24],"The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction, and then re-administering them to the patients. This therapy utilizes biotechnology to culture the immune cells of cancer patients in vitro and then re-infuse them back into the body, stimulating and enhancing the body's own immune function, killing and inhibiting cancer cells, eliminating small and residual lesions, or achieving the goal of treating cancer by significantly inhibiting the proliferation of residual cancer cells.",[87,27,88,61,89],"Lung Cancer (Locally Advanced or Metastatic)","Colorectal Cancer (Locally Advanced or Metastatic)","Advanced Solid Tumors",[89,91,92,93,94,95,96,97,98],"Metastatic Lung Cancer","Metastatic Liver Cancer","Metastatic Colorectal Cancer","Metastatic Breast Cancer","Autologous Immune Cell Therapy","Dendritic Cell Vaccine","CIK Cells","NK Cells","NOT_YET_RECRUITING","2025-11-20",{"date":102,"type":37},"2025-12-02",{"date":104,"type":21},"2025-12-01",{"date":106,"type":21},"2027-12-31",{"name":108,"class":74},"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd."]